Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 22, 2026.

Molecular Determinants and Dynamics of Hepatitis C Virus Secretion

Kelly E. Coller, Nicholas S. Heaton, Kristi L. Berger and 3 more

PLoS Pathogens · 2012

doi:10.1371/journal.ppat.1002466

Abstract

The current model of hepatitis C virus (HCV) production involves the assembly of virions on or near the surface of lipid droplets, envelopment at the ER in association with components of VLDL synthesis, and egress via the secretory pathway. However, the cellular requirements for and a mechanistic understanding of HCV secretion are incomplete at best. We combined an RNA interference (RNAi) analysis of host factors for infectious HCV secretion with the development of live cell imaging of HCV core trafficking to gain a detailed understanding of HCV egress. RNAi studies identified multiple components of the secretory pathway, including ER to Golgi trafficking, lipid and protein kinases that regulate budding from the trans-Golgi network (TGN), VAMP1 vesicles and adaptor proteins, and the recycling endosome. Our results support a model wherein HCV is infectious upon envelopment at the ER and exits the cell via the secretory pathway. We next constructed infectious HCV with a tetracysteine (TC) tag insertion in core (TC-core) to monitor the dynamics of HCV core trafficking in association with its cellular cofactors. In order to isolate core protein movements associated with infectious HCV secretion, only trafficking events that required the essential HCV assembly factor NS2 were quantified. TC-core traffics to the cell periphery along microtubules and this movement can be inhibited by nocodazole. Sub-populations of TC-core localize to the Golgi and co-traffic with components of the recycling endosome. Silencing of the recycling endosome component Rab11a results in the accumulation of HCV core at the Golgi. The majority of dynamic core traffics in association with apolipoprotein E (ApoE) and VAMP1 vesicles. This study identifies many new host cofactors of HCV egress, while presenting dynamic studies of HCV core trafficking in infected cells.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Hepatitis C virus (HCV) is a member of the Flaviviridae family that contains a single-stranded positive RNA genome (∼9600bp). This is translated into a polyprotein, which is processed by viral and host proteases into 3 structural proteins (core and the glycoproteins, E1 and E2) and 7 non-structural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). The discovery of HCV strains that are infectious in cell culture has enhanced the appreciation of the functions of these proteins in all stages of the viral life cycle –. Infection of hepatocytes in cell culture requires at least four potential receptor molecules, CD81, SR-B1, claudins, and occludin –. Additionally, numerous entry cofactors involved in receptor-mediated clathrin endocytosis are required –. Following endosomal acidification, genomic RNA is released into the cytoplasm where initial translation and replication occur. Replication is associated membranous structures derived from the endoplasmic reticulum (ER) called the membranous web,.

Following replication, genomic RNAs in complex with viral and possibly cellular proteins are thought to transit to lipid droplets (LD), where core protein localizes and virion assembly occurs –. Although primary functions of the NS proteins include viral RNA replication and host cell interactions, several NS proteins, including p7, NS2, NS3, and NS5A are also implicated in HCV assembly –. NS2 is a central regulator in capsid assembly that appears to act as a scaffold to coordinate interactions between the structural and non-structural proteins leading to viral RNA encapsidation,,. Capsid envelopment is thought to occur at the ER, in close juxtaposition to LDs, based on the subcellular localization of the E1 and E2 glycoproteins,.

The events following HCV assembly are less clear. The egress of flaviviruses through the secretory pathway is well documented and may be similar to the mechanism by which HCV is secreted,. However, HCV is distinct from the flaviviruses in that HCV particles are infectious upon envelopment and appear to be secreted from the cell in association with distinct lipid and apolipoprotein associations –. HCV particles circulating in the blood of infected patients are rich in triglycerides, apolipoprotein B (ApoB), and apolipoprotein E (ApoE), –. The low-density lipoprotein (LDL)-virus complex possesses a broad buoyant density, ranging between 1.03-1.25g/mL. Cell culture-derived virus also has a broad range of buoyant densities, with the lower density fractions containing virus highly infectious virus,,. Purified HCV virions have diverse morphologies ranging from 30-125 nm and a lipid composition resembling very low-density lipoprotein (VLDL),. The VLDL synthesis pathway has been implicated in infectious HCV secretion. Small interfering RNAs (siRNAs) or inhibitors that target components of VLDL synthesis, including microsomal triglyceride transfer protein, ApoB, and ApoE inhibit infectious HCV secretion,,,,,.

This study is a continuation of two previous RNAi studies in which membrane trafficking pathways were interrogated for their roles in HCV entry and replication,. In this study, we identified numerous host cofactors that are required for infectious HCV secretion, but not HCV entry or replication. We next developed a live cell imaging approach to study HCV core trafficking using an infectious HCV that contains a tetracysteine (TC) tag insertion in the core protein (TC-core). This approach has been successfully used before to visualize single virion HIV-1 budding – and vesicular stomatitis virus (VSV) endocytosis, without major defects in virus infectivity. TC-core movements that are dependent upon successful virion assembly were microtubule-dependent and associated with several components of the secretory pathway that were identified in the RNAi analysis.

Host genes involved in HCV secretion

This study is a part of a larger analysis, which interrogated a previously described unique siRNA library that targeted known membrane trafficking pathways,. The library consisted of 122 siRNAs targeted to membrane trafficking genes from Dharmacon, Inc and was supplemented with 18 additional genes important for replication and membrane organization in other viral systems. We first identified siRNAs that inhibited infectious extracellular HCV accumulation in a primary screen and then re-tested these siRNAs in secondary assays to identify the stage of the life cycle that they influenced. Genes involved in entry had a secondary phenotype in inhibiting HCV pseudoparticle (HCVpp) infection and genes involved in HCV replication had a defect in subgenomic replicon replication.

The primary screen was performed by electroporating four individual siRNAs per gene into Huh-7.5 cells and then allowing silencing for 48 or 72 hours before infection with HCV. Viral supernatants were collected at two days post infection (dpi) and viral titers were quantified via limiting dilution in at least two independent experiments, measured in duplicate, and normalized to at least 4 replicates of cells silenced with an irrelevant siRNA (siIRR) (Table 1). The siRNAs that inhibited extracellular infectious HCV production by more than 1 standard deviation of siIRR treated cells (>65% inhibition) were classified as “hits” and were characterized in secondary assays. To limit the possibility of siRNA off-target effects, individual siRNAs then were tested. We quantified cell viability using a luminescence-based assay that measures cellular ATP levels, following 5 days of silencing to eliminate phenotypes resulting from significantly decreased viability (p<0.001) (Figure S1).

In this study, genes that were required for infectious HCV production, but not HCVpp entry or replicon replication, were further tested for a role in infectious HCV secretion. We repeated the RNAi analysis and quantified intra- and extra-cellular HCV infectivity following HCV infection of siRNA-treated cells. Table 1 shows the ratio of intra- to extra-cellular virus, with a value greater than 1 indicating a defect in extracellular infectious HCV release. The titer of intracellular virus did not decrease significantly in these siRNA treatments as compared to siIRR (Figure S2), indicating the genes (Table 1) are not involved in HCV assembly, but rather the secretion of infectious particles.

The siRNA screen identified multiple components of the secretory pathway, from ER to Golgi trafficking (SAR1A), to Golgi structure and function (CYTH3), cargo sorting and vesicle budding from TGN (PRKD1, AP1M1, PI4KB, CLINT1), regulators of TGN to plasma membrane trafficking (RAB11A, RAB3D, PACSIN3), and the v-snare, VAMP1. This suggests that HCV virions egress through the secretory pathway from the TGN to recycling endosomes to the plasma membrane. A role for ER to Golgi trafficking genes, such as SAR1A, ARF3, and CYTH3, in the egress of infectious HCV is supported by previous data showing that brefeldin A treatment of infected cells accumulates intracellular infectious HCV. Additional genes cluster into actin and membrane remodeling pathways (RHOA, GIT1, WAS).

Construction and characterization of fluorescently labeled HCV core

To study the dynamics of HCV core trafficking in Huh-7.5 cells, a TC tag was fused in frame following amino acid three of the structural protein core in a derivative of J6/JFH-1, a chimeric genotype 2a isolate. The TC sequence of CCPGCC can coordinate biarsenical dyes, FlAsH and ReAsH. The TC-core virus replicates comparably to wild type (Figure 1A), with a mild impairment of infectious virus production (Figure 1B). ReAsH treatment of TC-core infected cells does not impair infectious virus production (Figure S3).

We first tested the specificity of labeling by examining whether FlAsH TC-core fluorescence overlapped with core detected by standard immunofluorescence. TC-core RNA was electroporated into Huh-7.5 cells and three days later the cells were treated with FlAsH biarsenical dye, then processed for immunofluorescence using a monoclonal antibody against HCV core (Figure 2A). Both antibody and FlAsH dye detected the same punctate structures located in the cytoplasm of infected cells and were not present in uninfected cells. Quantitation of FlAsH and anti-core puncta determined that 86.5% of the TC-core FlAsH signal overlapped with the core antibody fluorescence (Figure 2B), demonstrating specificity of the FlAsH staining.

The localization of HCV E2 relative to TC-core was analyzed by probing for TC-core with FlAsH dye and processing for immunofluorescence with a monoclonal antibody against E2 (Figure 2A). E2 expressed from the TC-core virus had the expected reticular pattern and was also found on a subset of cytoplasmic core puncta (Figure 2A) when we used an E2 antibody that detects E2 on assembled viral particles,, 21.8% of the TC-core signal overlapped with that of E2 fluorescence (Figure 2B). Some TC-core structures that were positive for E2 were found in the cell periphery, suggesting they may represent intracellular assembled viral particles. We then investigated whether we can visualize core and RNA, as would be expected for bona fide HCV virions. RNA localization was examined in wild type infected cells using “Click-iT” technology (Invitrogen) and cells were stained using an anti-core antibody (Figure 2B). We observe that 20.1% percent of anti-core colocalizes with RNA. Thus, sub-populations of core are associated with E2 and RNA, although we cannot conclude whether the observed RNA represents HCV genomes.

Next, we imaged TC-core movement in living cells. Huh-7.5 cells were electroporated with TC-core RNA, maintained for 72 hours, and stained with ReAsH dye followed by imaging using confocal microscopy. We chose to image at 72 hours post electroporation because TC-core was highly expressed and detectable by biarsenical dye staining and antibody detection (Figure 2A), maximal amount of virus was released as assessed by viral titer assay (Figure 1B), and HCV induced lipid droplet relocalization to the microtubule organizing center should have occurred indicating assembly of particles was initiated. Several TC-core particles are detectable in a whole cell image (Figure 2C) and a sub-population of particles displayed various movements at 72 hours post electroporation. The movements were either roughly static (Figure 2C particle 1), saltatory with many reversals in direction (Figure 2C particles 2–4), or directional movement (Figure 2C particle 5, Video S1). We then stained TC-core expressing cells with a RNA selective dye, Ribogreen, processed for ReAsH visualization of TC-core and then imaged in live cells. We observe co-trafficking of TC-core with the RNA dye, indicating that dynamic TC-core puncta associate with RNA (Figure 2D, Video S12).

NS2 is required for dynamic TC-core movements

We next tested whether the sub-population of dynamic TC-core movements require productive HCV virion assembly. As discussed earlier, multiple groups have published that HCV nonstructural (NS) protein 2, NS2, is required for HCV assembly by acting as a scaffold bridging structural and non-structural proteins,,,. The function of NS2 in assembly does not require its juxtaposition next to NS3 in the viral genome, such that HCV RNAs with an encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) inserted between NS2 and NS3 are infectious. Therefore, we constructed two additional viruses, a bicistronic HCV with the TC-core tag and a bicistronic TC-core version with a deleted NS2 (ΔNS2) (Figure 3A). RNAs were transcribed in vitro and electroporated into Huh-7.5 cells, then RNA replication and intra- and extra-cellular infectious virus were quantified over a time course. As expected, both bicistronic constructs were replication competent, (Figure 3B), while only the bicistronic virus containing NS2 was capable of producing infectious virus (Figure 3C).

HCV capsid assembly is dependent on the association of core with the lipid droplet. To examine the association of TC-core with lipid droplets, the various TC-core RNAs were electroporated into Huh-7.5 cells followed by staining with ReAsH dye and the neutral lipid stain (Bodipy 493/503) to detect lipid droplets prior to imaging. All constructs displayed core accumulation in large concentric rings or crescents around larger lipid droplets (Figure 4), indicating that TC-core had appropriate lipid droplet association.

We next examined whether the dynamic TC-core movements observed previously (Figure 2C) required HCV virion assembly. Timelapse fluorescence microscopy of individual TC-core puncta was performed 72 hours post electroporation with TC-core, bicistronic or ΔNS2 RNAs. Individual TC-core puncta (of which we can detect using an core antibody) were visualized by live cell confocal microscopy by capturing DsRed exposures every 2 seconds for several minutes (Videos S2–4). Biarsenical dye signal photobleached quickly, therefore timelapse acquisition was limited to short exposures over several minutes (usually up to 10 minutes). A sub-population of cytoplasmic TC-core puncta in cells electroporated with either TC-core or bicistronic RNAs displayed directional movements, whereas ΔNS2 TC-core puncta were static (Figure 5A) or displayed random movements. The TC-core puncta that displayed movements greater than 1 µm as a percentage of total core puncta in a cell was similar between the TC-core and bicistronic populations; 18.2%±1.22, n = 1010 at 72 hours post electroporation (hpe) for TC-core RNAs and 17.2%±1.6, n = 558, for bicistronic RNAs (Figure 5B). In contrast, the frequency of TC-core puncta expressed from the ΔNS2 virus that exhibit directed movement (greater than 1 µm) was virtually nonexistent, 0.65%±1.9, n = 617 (Figure 5B). Extended imaging of the ΔNS2 TC-core virus at 96 and 120 hours post electroporation did not show an increase in TC-core puncta movement (data not shown) indicating cytoplasmic movements of TC-core were dependent on NS2 function independent of viral kinetics.

The dynamics of TC-core trafficking were examined by distance from origin analysis. The cumulative distance traveled (in any direction) by a TC-core puncta during an imaging session was measured and plotted for each virus from a single particle. The distance from origin plots show core puncta in TC-core and bicistronic expressing cells had extensive total movements ranging from 3-17 microns per minute from the point of origin during an imaging session (Figure 5C). Core puncta expressed from the ΔNS2 virus displayed restricted movements ranging from 0-5 microns from the point of origin during imaging (Figure 5A,C), suggesting long range movements occur post assembly.

The individual run lengths and corresponding velocities of single particles were quantified by manual tracking. A run was defined as a period of uninterrupted transport lacking a pause. A pause was defined as a stop in motion greater than one frame, in this case 2 seconds between image acquisitions. TC-core puncta displayed saltatory (stop and start) movements with few processive runs and reversals where particles switched direction. The average run length displacement of wild type TC-core moving puncta was 2.457 µm ±.1215 (mean ± SEM, n = 154, Figure 6B) and fit a decaying exponential, R2 =.9924, which is consistent with microtubule associated transport. The average velocity of moving TC-core puncta was.1336 µm/second ±.010139 (mean ± SEM, n = 154, Figure 6A) and could be modeled by a Gaussian distribution, R2 =.9983. The TC-core dynamics of run length and the velocity are consistent with secretory vesicle trafficking (Figure S13),.

TC-core moves in association with microtubules

HCV core mediates redistribution of lipid droplets to the microtubule-organizing center (MTOC) by microtubule directed transport. The dynamics of peripheral TC-core movements are also suggestive of microtubule-dependent transport. To determine if TC-core puncta were associated with microtubules during transport, TC-core electroporated cells were stained with ReAsH at 72hpe and microtubules were visualized with TubulinTracker Green (Invitrogen). Figure 7A (Video S5) shows TC-core puncta movement associated with a microtubule (top). We next tested whether microtubule disruption with nocodazole treatment perturbs TC-core trafficking (Figure 7A-C, Videos S5 and S6). TC-core expressing cells were incubated with nocodazole, DMSO, or left untreated then TC-core puncta dynamics were recorded by timelapse imaging. The run lengths displayed by single particles were determined by manual tracking and the displacement between frames (distance) was plotted against time (Figure 7B). Both the untreated and DMSO treated cells showed similar core dynamics, in which core particles were static, randomly moving, or processively moving. Alternatively, nocodazole treatment dramatically decreased TC-core puncta dynamics (Figure 7A-C), where the majority of particles displayed static or random movements that did not result in long distance displacements.

TC-core traffics with components of the secretory pathway

We next validated the results of our RNAi analysis by examining the localization and trafficking of TC-core with cellular cofactors that were identified in the screen. A number of the cellular cofactors are involved in Golgi function and sorting at the TGN, including, CYTH3, PI4KB, PRKD1, and AP1M1. We first examined whether TC-core colocalizes with Golgi markers.Huh-7.5 cells that were electroporated with TC-core RNAs were examined for localization with the Golgi markers Golgi-GFP (Invitrogen, Golgi and Golgi stacks) or GM130 (cis- face of the Golgi) (Figure 8). We observe that a sub-population of TC-core colocalizes with the Golgi. The overall frequency of colocalization is relatively low, as would be expected for a transient association of core with the Golgi.

The role of exit from the Golgi in TC-core trafficking was assessed by quantifying the effects on TC-core movements in the presence of inhibitors of two genes identified in the RNAi screen: brefeldin A (BFA), which inhibits ARF3, and PIK93, which inhibits PI4KB. BFA treatment inhibits secretion of viral particles. PI4KB is a resident Golgi lipid kinase that is important in trafficking from the Golgi to the plasma membrane. PIK93 is a selective inhibitor of the type III PI4 kinase, PIK4B, at the concentration used in this experiment (.5 µM),. Treatment with BFA or PIK93 significantly reduced the average velocity of motile TC-core puncta (Figure 8B), further supporting a role of the secretory pathway in HCV secretion.

We next examined the trafficking of TC-core with ApoE, a component of VLDL secretion. ApoE is required for HCV infection and is associated with extracellular infectious HCV virions –,,. The association of HCV and lipoproteins is thought to occur early during assembly, then HCV is secreted as a lipo-viroparticle,,,,, –. In normal hepatocytes, ApoE exits the cell by using the secretory pathway and can also transit through the recycling endosomal pathway, –. ApoE is also associated with VLDL particles during secretion and with secretory vesicles leaving the Golgi where VLDL particles mature. We constructed a C-terminal GFP fusion to ApoE, ApoE-GFP, to determine if TC-core puncta traffic with ApoE in live cells. ApoE-GFP had a cytoplasmic localization that could be detected with an ApoE antibody (Figure S4). TC-core expressing cells were transfected with ApoE-GFP at 48hpi followed by live cell imaging at 72hpi. Dynamic TC-core puncta (from transfected and infected cells) were found to colocalize with ApoE-GFP (Figure 9a, Figures S5 & S11, Videos S7 & S13) in the cell periphery. This observation suggests that ApoE is associated with de novo forming HCV particles during secretion instead of being acquired extracellularly. We determined the percentage of TC-core puncta moving with ApoE-GFP to be 81.25%±8.98, n = 26/32 of moving TC-core puncta. We also investigated colocalization of core with ApoB. Although some colocalization of core and ApoB was observed in the proximity of lipid droplets, little colocalization between core and ApoB occurred in the periphery (Figure S6).

A gene identified in the RNAi screen to be required for extracellular release of infectious HCV was Rab11A, a small GTP binding protein. Rab11A modulates transport through the recycling endosome, associates with apical targeting in polarized cells, and is involved in transporting cargoes from the Golgi to the plasma membrane. Rab11 is required for budding of influenza virus, hantavirus release, and involved in the vesicular trafficking of Sendai virus ribonucleocapsids. We constructed a N-terminal GFP fusion to Rab11A, and imaged TC-core and Rab11A cotrafficking by timelapse fluorescence microscopy (Figure 9B, Figures S4 & S7, Videos S8 and S14). GFP-Rab11a had a cytoplasmic localization that was either associated with the Golgi network or alone in puncta (Figure S4). We also visualized TC-core with a second marker of the recycling endosome, transferrin. TC-core electroporated Huh-7.5 cells were incubated with Alexa Fluor 488 conjugated transferrin, and cotrafficking of TC-core and transferrin was imaged using live cell microscopy (Figure 9C, Figure S8, Video S9). We determined the percentage of moving TC-core puncta associated with Rab11a and transferrin 488 markers to be 61.2%±8.7% (n = 19/31 of moving TC-core puncta) and 50.0%±5.3% (n = 44/88 of moving TC-core puncta), respectively. The cotrafficking of TC-core with markers of the recycling endosome validates the RNAi data that implicates a role for the recycling endosome in infectious HCV secretion.

Although the cotrafficking of TC-core with various cellular markers was initially done in cells electroporated with TC-core HCV RNAs, we subsequently confirmed co-trafficking the results following infection with TC-core virus (Figure S11). We next tested whether the defects in infectious HCV production following Rab11a silencing were associated with altered core trafficking. Huh-7.5 cells were electroporated with Rab11a siRNAs, maintained for two days, infected with HCV for two days, fixed and probed with antibodies to core and the Golgi marker GM130. We observe an increase in core accumulation at the Golgi following Rab11a silencing (Figure 10A,C, 30.2±5.5% (n = 1350)) of Golgi stacks are core positive in siIRR treated cells versus 55.7±7.4% (n = 1517) in siRab11a treated cells. Thus, the defect in infectious HCV release in siRab11a treated cells correlates with an accumulation of core in the Golgi network.

Vesicular associated membrane 1 (VAMP1) was identified as a cofactor in the release of extracellular infectious HCV in our RNAi screen. VAMP1 can complex with syntaxins and SNAP25 to form a SNARE complex involved in docking and/or fusion of vesicles at the plasma membrane. We constructed a N-terminal GFP fusion to VAMP1 and visualized cotransport of GFP-VAMP1 and TC-core (Figure 9D, Figure S9, Video S10 and S15). GFP-VAMP1 localized to puncta in the cytoplasm and could be detected using an anti-VAMP1 antibody (Figure S4). We found a high percentage of TC-core puncta (79.4% ± 8.90 n = 135/170 of moving TC-core puncta) co-trafficking with GFP-VAMP1 in the cell periphery suggesting that TC-core is transported in VAMP1 associated vesicles. It is well established that the secretory and endosomal pathways intersect to deliver vesicular cargoes to the plasma membrane. To determine if TC-core puncta transported in the lumen of a vesicle, we incubated TC-core electroporated cells with dextran and found that the dynamic TC-core trafficked with dextran (Figure 9E, Figure S10, Supplemental Video S11) with a frequency of 82.5%± 6.0% (n = 33/40 moving TC-core puncta). This evidence further supports that core is vesicle-associated during secretion.

Finally, we tested whether silencing the Golgi lipid kinase PI4KB would decrease the association of core with VAMP1. siRNA treated cells were transfected with GFP-VAMP1, infected with wild type HCV for two days and processed for core and GFP-VAMP1 imaging. We observed extensive colocalization of core and GFP-VAMP1 (65.1±2.5% (n = 366)) in siIRR treated cells (Figure 10B and D). However in cells treated with siPIK4B, fewer core and GFP-VAMP1 colocalization (19.2±2.3% (n = 286)) was observed (Figure 10B and D). Thus, PI4KB expression is required for core colocalization with VAMP1.

Discussion

This study combined a RNAi analysis to identify host genes involved in the release of infectious HCV from cells with live cell imaging of HCV core trafficking in order to assess the dynamics and cellular pathways involved in HCV egress. The data from the RNAi screen delineates an egress pathway for HCV that heavily interplays with the constitutive secretory pathway, which is suggested for other viruses in the Flaviviridae (reviewed in ). If we align the cellular cofactors of HCV egress along the constitutive secretory pathway and also supplement with data from the literature, the following molecular model of infectious HCV secretion in Huh-7.5 cells is attained. HCV is hypothesized to initiate assembly in close association with lipid droplets by coating lipid droplets with the core protein and bringing together nonstructural and structural proteins in a NS2-dependent manner,,. Following capsid assembly, nascent virions bud into the lumen of the ER where the glycoproteins E1/E2 reside in addition to the VLDL secretion machinery. HCV is infectious upon envelopment at the ER, and it is thought that ApoE is acquired early during assembly because knockdown of ApoE reduces intracellular and extracellular virus; also NS5A interacts with ApoE,. We found through live cell imaging TC-core cotransports extensively with ApoE-GFP (Figure 9A). In addition, ApoE localizes to large, static, crescent shaped accumulations of core presumably associated with lipid droplets (Figure S12). Our data does not clearly distinguish whether HCV hijacks the intact VLDL secretion pathway or associates with ApoE through the NS5A interaction; however, the absence of ApoB colocalization with TC-core puncta is more supportive of the latter model (Figure S6).

The maturation of HCV particles overlaps with other aspects of VLDL secretion. Nascent VLDL particles undergo further lipidation and maturation in the Golgi, followed by ER to Golgi trafficking dependent on SAR1A. Our RNAi screen implicated SAR1A in the production of extracellular HCV suggesting HCV particles transport from the ER to the Golgi with COPII secretory vesicles. The Golgi is further associated with HCV secretion by the genes CYTH3, ARF3, AP1M1, PI4KB, and PRKD1. During secretion, ARF GTPases such as CYTH3 and ARF3 are activated then localize to the TGN where they can interact with coat proteins, such as AP1M1 to initiate vesicle budding and sorting (reviewed in ). Treatment of HCV infected cells with brefeldin A, which can inhibit ARF3, results in the inhibition of infectious extracellular virus release. We visualized association of TC-core particles with TGN markers. In contrast to a recent study, we did not find evidence of Golgi disruption in either wild type HCV or TC-core (Figure 8) infected cells and we found PRKD1 to be required for HCV release. PI4KB (phosphatidylinositol kinase IIIβ) appears to influence the replication of some HCV genotype 1 isolates,. We observe that in the case of J6/JFH1 infection, it plays a role in egress, and not in entry or replication. We cannot discount the possibility that some of the siRNA treatments may affect secondary functions, such as the post-translational modifications of viral proteins.

Following maturation of particles in the TGN, cargoes are sorted into secretory vesicles en route to the plasma membrane. Rab GTPases are master regulators of intracellular vesicle trafficking, and we found that Rabs 11A and 3D were required for efficient secretion of HCV. Rab11A positive recycling endosomes sort some vesicles during exocytosis (reviewed in ) to apical and basolateral membranes. We found TC-core puncta colocalized with GFP-Rab11A and transferrin-488, a marker for the recycling endosome, and some of these puncta displayed directional transport (Figure 9B). The transient nature of the interaction may be attributed to the recycling endosome serving as a sorting station for membrane bound cargoes. Silencing Rab11a leads to the increased accumulation of core in the Golgi, further supporting a model wherein HCV virions bud from the TGN and are transported to the recycling endosome.

VAMP1 and Rab11A were implicated in ours and other RNAi screens for host factors involved in HCV propagation. VAMP1 is a v-snare that is loaded onto secretory vesicles at the TGN and mediates the fusion of the vesicle with the plasma membrane by interacting with SNAP-25 and syntaxins. We found a dynamic sub-population of TC-core that transports long-range distances with GFP-VAMP1. TC-core also cotransports with dextran, which also indicates vesicle association. Interestingly, HCV core has been shown to localize with early and late endosomal markers during egress time points and the release of extracellular virus depended on endosome motility. We have confirmed that a smaller sub-population of TC-core cotraffics with Rab5a-GFP labeled early endosomes (data not shown), however, the interpretation of this data is complicated by the core-rab5A interactions observed during endocytosis. Due to the design of the screen (excluding genes involved in HCVpp entry or replicon replication), it is possible that some genes with multiple roles in the viral life cycle were overlooked.

Trafficking of secretory vesicles and TC-core both require intact microtubules (Figure 7). This is also supported by the observation that the release of infectious extracellular HCV is disrupted by depolymerization of microtubules. We also found genes involved in actin dynamics (RHOA, GIT1, WAS) to play a role in HCV secretion. It is not thought actin dynamics are responsible for the long-range transport we recorded for the TC-core virus, but actin may play a role in the biogenesis of transport vesicles (reviewed in ) and fusion of secretory vesicles at the plasma membrane.

The dynamics of TC-core movements are consistent with vesicular trafficking in the Huh-7.5 cells (Figure S13). HCV particles, especially as lipo-viroparticles, are too large to freely diffuse through the cytoplasm; instead they likely rely on microtubules for long-range transport. Secreted HCV particles may have several associated microtubule motors because TC-core puncta display bidirectional transport. Because the majority of TC-core puncta moving towards the plasma membrane (plus-end transport) displayed a velocity curve that could be modeled by a Gaussian distribution, a single class of plus ended motors is most likely involved. Association of a minus-end motor is likely since particles displayed bidirectionality, but we cannot rule out mixed microtubule polarity in our Huh-7.5 cells.

Transport rates for TC-core puncta are below what has been published for other viruses. Neurotropic herpesviruses display transport kinetics consistent with fast axonal transport (2 µm/sec), which does not occur in hepatocytes, and vaccinia virus displays slower saltatory movements (1-3 µm/sec) (reviewed in ). In our study, we found HCV core to move at rates similar to Vamp-1 and ApoE-associated vesicles in Huh-7.5 cells (Figure S13). Long-range transport to the plasma membrane represented a net plus-end movement that is comprised of small steps along the microtubule. The slow rates of TC-core movement that we recorded can be better resolved with higher spatial and temporal resolutions, as we were only imaging rates of 1 frame per 2 seconds.

Previous characterization of HCV JC1 infection found less core localization at lipid droplets and more ER localization than is observed in HCV JFH1 infection. This was interpreted as possibly reflecting differences in the sites of assembly for HCV JC1 and JFH1. In our experiments, the TC-core from JC1 clearly localizes at lipid droplets, in addition to the ER, Golgi, and other secretory components. The predominant subcellular localization of core that is observed in fixed cell microscopy does not necessarily indicate a site of virion assembly, it simply reflects which stage in core trafficking is rate limiting. For instance, a slightly different interpretation is that JFH1 assembles virus at a lower efficiency than JC1, therefore more core is at the lipid droplet awaiting completion of virion assembly. Since JC1 virion assembly is more efficient than JFH1, more core is localized to other subcellular compartments involved in core trafficking, such as the ER. In support of this interpretation, our TC-core virus has a higher amount of lipid droplet localization than the parental JC1 due to slightly less efficient virion assembly.

We plan to revisit the trafficking studies in a more relevant polarized hepatocyte cell culture system. Hepatocytes in vivo possess complex architecture that consists of distinct basolateral (sinusoidal) and apical (canalicular) plasma membrane domains, which are separated by tight junctions. The association of apical membranes from neighboring cells forms bile caniculi. With complex polarity, also comes complex trafficking of proteins to apical and basolateral membranes. Two pathways are used to direct proteins to the apical membrane in hepatocytes, a direct route or through transcytosis after reaching the basolateral membrane. HCV is known to spread via two distinct routes, extra-cellular release and cell-cell spread,. Future studies will characterize the cell-cell spread trafficking pathway and examine whether HCV undergoes selective polarized trafficking to ultimately spread through an extracellular (basolateral) or intracellular (apical) intermediate.

Virus and cells

Huh-7.5 cells were grown in Dulbecco's modified high glucose media (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS; Invitrogen), nonessential amino acids (NEAA, 0.1 mM; Gibco), and 1% penicillin-streptomycin (Invitrogen). Viral RNA was electroporated into Huh-7.5 cells as described previously,. Viral supernatants were collected daily from up to 5 passages of electroporated cells, filtered through a.22 µm nitrocellulose filter, and kept at 4°C protected from light.

Plasmid constructs

pJFHxJ6-CNS2C3 (WT) is a HCV genotype 2a infectious clone where core through the first transmembrane domain of NS2 of a JFH-1 backbone was replaced with J6 genotype sequence. A full length (FLNCCPGCCMEP) tetracysteine (TC) tag was inserted into the HCV core gene after amino acid 3 by amplifying two regions (5′ and 3′ of the tag) and joining the two regions with an ApaLI restriction site proximal to the tag insertion site. The full length TC tag has been shown to enhance binding of biarsenical dyes. The 5′ region was amplified using 5′ AACGAATTCTAATACGACTCACTATAGACC and 5′ AACGTGCACGGTCTACGAGACCTCCCGGGG (EcoRI and ApaLI sites underlined). The 3′ region was amplified using 5′ AACGTGCACCATGAGCACATTTCTCAATTGTTGTCCTGGCTGTTGTATGGAACCTAATCCTAAACCTCAAAGAAAAACC and 5′ AACCGTACG CCAAGATCATGGTAGCCGTGG (ApaLI and BsiWI sites underlined, TC tag bolded). The 5′ and 3′ regions were digested with ApaLI and ligated together to form the full-length core region with the tag inserted. The TC-core fragment was subsequently cloned into JFHxJ6NS23 using the EcoRI and BsiWI sites and the TC tag insertion was confirmed by sequencing. The bicistronic construct was constructed by insertion of a HCV genotype 2a IRES – NS2 fragment into a subgenomic replicon, pSGR-JFH1-neo, containing the encephalomyocarditis virus (EMCV) IRES through the HCV replicase genes NS3-NS5B. The IRES-NS2 fragment was PCR amplified by using the primers 5′ACCGAATTCTAATACGACTCACTATAGACCTGCCCCTAATAG and 5′ ACCGTTTAAACTTAAAGGAGCTTCCACCCCTTGGAGGTGTAGCCATCAGCTGG (EcoRI and PmeI sites are underlined). The subsequent fragment was subcloned in the replicon resulting in the bicistronic construct. The NS2 deletion construct was made by two-part subclone. NS2 was deleted by insertion of the HCV genotype 2a IRES-p7 genes into a subgenomic replicon as stated above. The IRES-p7 region was PCR amplified by using the same EcoRI primer as above and 5′ ACCGTTTAAACTTAAGCATAAGCCTGTTGGGGCAATGCTAGGAGCAGTAGGCTA (PmeI site underlined) which goes through p7. The resulting PCR fragment was cloned in the subgenomic replicon stated above. This resulted in the NS2 deletion virus in a bicistronic backbone. The TC-tagged core was introduced by digestion of the TC-core virus with EcoRI and BsiWI to liberate a DNA fragment containing TC-core through part of glycoprotein E1. Untagged core in the NS2 deletion backbone was replaced with the TC-core fragment using the corresponding EcoRI and BsiWI restriction sites. This resulted in a TC-core NS2 deletion (ΔNS2) construct. The resulting clone was sequenced to verify in frame insertion of the tag and presence of the deletion.

Apolipoprotein E was PCR amplified from a human ORF clone, accession number EL733202 (Open Biosystems), using the primers 5′ ACGAATTCATGAAGGTTCTGTGGGCTGC (EcoRI site is underlined) and 5′ GTGGATCC CGTGATTGTCGCTGGGCAC (BamHI site is underlined, bold indicates a 1nt insertion). The PCR product was cloned into pEGFP-N2 at the EcoRI and BamHI sites to create ApoE-GFP, and then confirmed by sequencing. Rab11A was PCR amplified from a human ORF clone, accession number CV027643 (Open Biosystems), using the primers 5′ ACCAAGCTTCGATGGGCACCCGCGACGACGAGTACGAC (HindIII site is underlined) and 5′ ACCGGTACCTTAGATGTTCTGACAGCACTGCACCTT (KpnI site is underlined). The PCR product was cloned into pmGFP-C1, resulting in GFP-Rab11A and confirmed by sequencing. VAMP1 ORF was PCR amplified from a human ORF clone, accession number CV029376 (Open Biosystems), using the primers 5′ GCAGATCT ATGTCTGCTCCAGCTCAGCCACC (BglII site is underlined) and 5′ GCAAGCTT TCAGCGATACTTACTTACAATAAC (HindIII site is underlined). The resulting PCR product was cloned into pEGFP-C1 using the BglII and HindIII sites to result in GFP-VAMP1 and confirmed by sequencing.

Viral replication curve and TCID50/mL

WT, TC-core, bicistronic, and ΔNS2 RNAs were transcribed in vitro as described. Huh-7.5 cells were electroporated with 2 µg/µl of each viral RNA and plated into 96 well plates. Viral supernatants were collected at indicated times post electroporation and titered by limiting dilution and immunohistochemical staining using an antibody directed to NS5A (9E10) as described,. For intracellular infectious virus, the cells went through three freeze-thaw cycles prior to titering. For RNA quantitation, cells were washed twice with PBS and lysed in RLT lysis buffer (Qiagen) at indicated timepoints. RNA was isolated using the RNAeasy kit (Qiagen). RNA copy number was determined by reverse transcriptase (RT) PCR analysis as described previously, using the Platinum qRT-PCR Thermoscript One-Step System (Applied Biosystems). 2 µL of extracted RNA was detected using the following primers and probe: forward 5′ ACTTCATTAGCGGCATCCAATAC; reverse 5′-CGGCACTGAATGCCATCAT; probe 5′-6FAM-CAGGATTGTCAACACTGCCAGGGAACC - (Iowa Black), amplifies from the NS4 gene. PCR conditions were 50°C for 30 minutes, 95°C for 6 minutes, and (95°C for 15 seconds followed by 60°C for 1 minute) x 50 cycles.

RNA interference assay

The siRNAs used are listed in Table S1. The methods for the primary RNAi screen have been previously described,. Briefly, the primary screen included pools of four siRNAs that target 140 membrane trafficking genes (Dharmacon, Inc.). Genes important for infectious HCV production were subsequently silenced with four individual siRNAs targeting the gene to validate the RNAi results. 1×106 Huh-7.5 cells in 0.05 ml of PBS pH 7.4 were electroporated with 125 picomoles of siRNA for 5 pulses of 770 volts for 99 microseconds with one- second intervals on a BTX 830 electroporator with 96-well attachment. Cells were infected 72 hours after electroporation with a multiplicity of 0.5 infectious HCV particles per cell for 6 hours, rinsed with media, then maintained for 2 days at 37°C. 48 hours after infection, the supernatants were collected and analyzed for infectious virus via limiting titer dilution as described previously. Host gene expression knockdown was assessed using the primer – probe sets listed in Table S2.

For visualization of core localization during silencing, cells were silenced with siRNAs followed by infection and immunofluorescence. Briefly, Huh-7.5 cells were electroporated (as above) with 2 pre-validated RAB11a siRNAs (Ambion, ID: s16073 and 14940), 2 pre-validated PIK4B siRNAs (Ambion, ID: 283 and s10543), or irrelevant siRNA and silencing was established for 48 hours. Electroporated cells were infected with HCV then maintained for 2 days, followed by seeding onto coverslips, fixation, and immunofluorescence staining.

Immunofluorescence

HCV TC-core infected cells stained with biarsenical dye were fixed in 4% paraformaldehyde for 10 min, permeabilized in 0.2% Triton X-100 in PBS for 20 minutes, and blocked with 0.1% Tween-20 and 10% goat serum in PBS for 30 min. Cell were washed with PBS plus 0.1% Tween-20 (PBST) after blocking and between antibody incubations. Primary and secondary antibodies were diluted in PBST. For detection of core, a mouse monoclonal antibody (#1851 Virostat, Portland, ME) was used at a dilution of 1∶50, mouse monoclonal antibody to NS5A (9E10) was used at a dilution of 1∶1000, dsRNA antibody (J2, English and Scientific Consulting Bt) was used at 1∶1000, and a human monoclonal antibody to E2 (Steve Foung) was used at 1∶250. GFP fusion proteins were assessed for correct localization by incubation with antibodies. Anti-Apolipoprotein E (Abcam) was used at a dilution of 1∶250, anti-Vamp1 (Abcam) was used at a dilution of 1∶250, anti-Rab11a (Invitrogen) was used at a dilution of 1∶250, anti-GM130 (Abcam) was used at 1∶250 to label the Golgi network, and anti-ApoB was used at a dilution of 1∶250. Alexa-488 or Alexa-594 conjugated IgG (Molecular Probes, Eugene, OR) secondary antibodies were diluted 1∶1000. Golgi-GFP (Invitrogen) was used to label the TGN by the recommended directions. Bodipy 493/503 was used to label neutral lipids (lipid droplets) in both fixed and live cell images at a concentration of 20 µg/ml.

Biarsenical dye labeling of HCV expressing cells

FlAsH or ReAsH labeling was performed per the instructions provided in the TC-tag detection kit (Invitrogen). At 72 hours post electroporation, cells were washed once with Opti-MEM (Invitrogen) and labeled with biarsenical dye (1.25 µM) in Opti-MEM. Cells were incubated at 37°C for 30 minutes, then washed two times with 1X BAL (2,3-dimercapto-1-propanol) wash buffer (supplied in the kit, Invitrogen) supplemented with 500 µM EDT in Opti-MEM for 5 minutes. The wash buffer was removed and the cells were washed one time using Opti-MEM followed by incubation with prewarmed media.

Tracking of TC-core in the presence of drug inhibitors of the secretory pathway was performed as follows: TC-core electroporated cells were incubated with DMSO, GolgiPlug containing BFA (1 µg/mL, BD Biosciences), or PIK93 (0.5 µM, Tocris) for 2 hours prior to staining with ReAsh. DMSO or drug was present during time of staining and in the imaging media.

RNA labeling

Infected cells were incubated with Click-iT RNA Alexa Fluor 488 Imaging Kit (Invitrogen) to visualize RNA. Briefly, infected cells were seeded on round coverslips and incubated with Click-iT kit as per manufacturer's instructions in the presence of actinomycin D (1 µg/ml). Cells were processed for immunofluoresence after Click-iT labeling.

Fluorescence microscopy

All images were acquired with an Olympus DSU spinning disk confocal microscope fitted with a 100×1.45 N.A oil-immersion objective. FlAsH labeled core was detected using the EGFP filter set (ex: 480/25 and em: 525/40), whereas ReAsH labeled core was visualized with the DsRed filter set (ex: 565/25 and em: 620/60) coupled to a Hamamatsu back-thinned EM-CCD high speed/sensitivity camera. Slidebook software was used for image acquisition and processing (Intelligent Imaging Innovations, Inc, Denver, CO).

Immunofluorescence imaging of TC-core with viral or host markers was accomplished by acquiring sequential static images with DsRed, EGFP, and 350 filter set sequential exposures.

Live cell imaging of TC tagged HCV was performed by growing infected cells on polylysine treated 35 mm glass bottom Fluorodishes (World Precision Instruments). Cells were stained with biarsenical dye as above except imaging media (DMEM-F12- Invitrogen) supplemented with 10% fetal bovine serum, 0.1 mM nonessential amino acids, 1% penicillin-streptomycin, and 25 mM HEPES was added following the final wash. Imaging chambers were sealed with parafilm before imaging. Cells were maintained on a heated stage set at 37°C. Timelapse imaging of TC-core particles and GFP labeled host proteins was taken by sequential imaging every 2 seconds with 200 ms exposures for each channel, DsRed and GFP respectively. In some cases cells were incubated with transferrin-488 (5 µg/mL, Invitrogen) or phrododextran (10 µg/mL, Invitrogen) prior to imaging as per manufacturer's instructions.

Individual core puncta transport velocities and run lengths were calculated by kymograph analysis. Briefly, the multiple kymograph plugin for ImageJ was used to generate kymographs. Runs were defined as uninterrupted diagonal lines and the distance traveled (length) and the average velocity (slope) were measured. The frequency of TC-core puncta movement was measured by quantifying the number of TC-core puncta displaying a run length greater than 1 µm as a percentage of total cellular TC-core puncta signal using the analyze particles tool in ImageJ per imaging session. Distance from origin plots were generated by using the Manual Tracking plugin for Image J, measuring the distance traveled (in any direction) between frames for a respective TC-core puncta. Values were added and plotted against time. Manual Tracking plugin was also used to generate the distance versus time plots. Distance between timepoints was plotted versus time.

Statistical analysis

Prism software was used to plot and determine p-values for replication and TCID50/mL titer curves. The velocity and run length plots were also done using Prism software where the data was modeled to a Gaussian distribution or a decaying exponential.

References 93

  1. 1.

    Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. Complete replication of hepatitis C virus in cell culture. Science. 2005;309:623-626.

    Not in our library10.1126/science.1114016

  2. 2.

    Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A. 2006;103:3805-3809.

    Not in our library10.1073/pnas.0511218103

  3. 3.

    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791-796.

    Not in our library10.1038/nm1268

  4. 4.

    Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005;102:9294-9299.

    Not in our library10.1073/pnas.0503596102

  5. 5.

    Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003;197:633-642.

    Not in our library10.1084/jem.20021756

  6. 6.

    Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007;446:801-805.

    Not in our library10.1038/nature05654

  7. 7.

    Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009;457:882-886.

    Not in our library10.1038/nature07684

  8. 8.

    Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem. 2003;278:41624-41630.

    Not in our library10.1074/jbc.m305289200

  9. 9.

    Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol. 2006;80:6964-6972.

    Not in our library10.1128/jvi.00024-06

  10. 10.

    Codran A, Royer C, Jaeck D, Bastien-Valle M, Baumert TF, et al. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol. 2006;87:2583-2593.

    Not in our library10.1099/vir.0.81710-0

  11. 11.

    Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol. 2006;80:11571-11578.

    Not in our library10.1128/jvi.01717-06

  12. 12.

    Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol. 2002;76:5974-5984.

    Not in our library10.1128/jvi.76.12.5974-5984.2002

  13. 13.

    Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol. 2003;77:5487-5492.

    Not in our library10.1128/jvi.77.9.5487-5492.2003

  14. 14.

    Rouille Y, Helle F, Delgrange D, Roingeard P, Voisset C, et al. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol. 2006;80:2832-2841.

    Not in our library10.1128/jvi.80.6.2832-2841.2006

  15. 15.

    Boulant S, Targett-Adams P, McLauchlan J. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol. 2007;88:2204-2213.

    Not in our library10.1099/vir.0.82898-0

  16. 16.

    Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, et al. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology. 2002;292:198-210.

    Not in our library10.1006/viro.2001.1225

  17. 17.
  18. 18.

    Moradpour D, Englert C, Wakita T, Wands JR. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology. 1996;222:51-63.

    Not in our library10.1006/viro.1996.0397

  19. 19.

    Ma Y, Yates J, Liang Y, Lemon SM, Yi M. NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly. J Virol. 2008;82:7624-7639.

    Not in our library10.1128/jvi.00724-08

  20. 20.
  21. 21.

    Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol. 2007;81:8374-8383.

    Not in our library10.1128/jvi.00690-07

  22. 22.

    Stapleford KA, Lindenbach BD. Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J Virol. 2011;85:1706-1717.

    Not in our library10.1128/jvi.02268-10

  23. 23.
  24. 24.

    Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol. 2008;82:7964-76.

    Not in our library10.1128/jvi.00826-08

  25. 25.
  26. 26.
  27. 27.

    Hughes M, Griffin S, Harris M. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol. 2009;90:1329-1334.

    Not in our library10.1099/vir.0.009332-0

  28. 28.

    Bartenschlager RPF, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011;19:95-103.

    Not in our library10.1016/j.tim.2010.11.005

  29. 29.

    Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007;9:1089-1097.

    Not in our library10.1038/ncb1631

  30. 30.

    Lindenbach BD TH-J, Rice CM, Knipe DMHP. Flaviviruses: the viruses and their replication;. 2007;1101-1152.

    Not in our library

  31. 31.

    Mackenzie JM, Westaway EG. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol. 2001;75:10787-10799.

    Not in our library10.1128/jvi.75.22.10787-10799.2001

  32. 32.

    Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol. 2007;81:13783-13793.

    Not in our library10.1128/jvi.01091-07

  33. 33.

    Jiang J, Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol. 2009;83:12680-12691.

    Not in our library10.1128/jvi.01476-09

  34. 34.

    Merz A, Long G, Hiet MS, Brugger B, Chlanda P, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem. 2011;286:3018-3032.

    Not in our library10.1074/jbc.m110.175018

  35. 35.

    Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, et al. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol. 2008;82:2120-2129.

    Not in our library10.1128/jvi.02053-07

  36. 36.

    Huang H, Sun F, Owen DM, Li W, Chen Y, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A. 2007;104:5848-5853.

    Not in our library10.1073/pnas.0700760104

  37. 37.

    Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramiere C, et al. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS ONE. 2009;4:e4233.

    Not in our library10.1371/journal.pone.0004233

  38. 38.

    Diaz O, Delers F, Maynard M, Demignot S, Zoulim F, et al. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol. 2006;87:2983-2991.

    Not in our library10.1099/vir.0.82033-0

  39. 39.

    Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol. 2002;76:6919-6928.

    Not in our library10.1128/jvi.76.14.6919-6928.2002

  40. 40.

    Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, et al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol. 2010;84:10999-11009.

    Not in our library10.1128/jvi.00526-10

  41. 41.

    Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology. 2005;41:265-274.

    Not in our library10.1002/hep.20542

  42. 42.

    Mancone C, Steindler C, Santangelo L, Simonte G, Vlassi C, et al. Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins. Gut. 2011;60:378-386.

    Not in our library10.1136/gut.2010.211292

  43. 43.
  44. 44.

    Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, et al. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A. 2009;106:7577-7582.

    Not in our library10.1073/pnas.0902693106

  45. 45.

    Arhel N, Genovesio A, Kim KA, Miko S, Perret E, et al. Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes. Nat Methods. 2006;3:817-824.

    Not in our library10.1038/nmeth928

  46. 46.
  47. 47.

    Turville SG, Aravantinou M, Stossel H, Romani N, Robbiani M. Resolution of de novo HIV production and trafficking in immature dendritic cells. Nat Methods. 2008;5:75-85.

    Not in our library10.1038/nmeth1137

  48. 48.

    Mire CE DD, Delos SE, White JM, Whitt MA. Glycoprotein-dependent acidification of vesicular stomatitis virus enhances release of matrix protein. J Virol. 2009;83:12139-12150.

    Not in our library10.1128/jvi.00955-09

  49. 49.

    Das SC PD, Nayak D, Pattnaik AK. Biarsenical labeling of vesicular stomatitis virus encoding tetracysteine-tagged m protein allows dynamic imaging of m protein and virus uncoating in infected cells. J Virol. 2009;83:2611-2622.

    Not in our library10.1128/jvi.01668-08

  50. 50.

    Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, et al. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol. 2000;74:10407-10416.

    Not in our library10.1128/jvi.74.22.10407-10416.2000

  51. 51.
  52. 52.

    Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology. 2003;125:1808-1817.

    Not in our library10.1053/j.gastro.2003.09.023

  53. 53.

    Wacker I, Kaether C, Kromer A, Migala A, Almers W, et al. Microtubule-dependent transport of secretory vesicles visualized in real time with a GFP-tagged secretory protein. J Cell Sci. 1997;110(Pt 13):1453-1463.

    Not in our library10.1242/jcs.110.13.1453

  54. 54.

    Welte MA. Bidirectional transport along microtubules. Curr Biol. 2004;14:R525-537.

    Not in our library10.1016/j.cub.2004.06.045

  55. 55.

    Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, et al. Hepatitis C Virus Core Protein Induces Lipid Droplet Redistribution in a Microtubule- and Dynein-Dependent Manner. Traffic. 2008;9:1268-1282.

    Not in our library10.1111/j.1600-0854.2008.00767.x

  56. 56.

    Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733-747.

    Not in our library10.1016/j.cell.2006.03.035

  57. 57.

    Toth B, Balla A, Ma H, Knight ZA, Shokat KM, et al. Phosphatidylinositol 4-kinase IIIbeta regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J Biol Chem. 2006;281:36369-36377.

    Not in our library10.1074/jbc.m604935200

  58. 58.

    Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, et al. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem. 1999;274:35711-35718.

    Not in our library10.1074/jbc.274.50.35711

  59. 59.

    Benga WJ, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology. 2010;51:43-53.

    Not in our library10.1002/hep.23278

  60. 60.

    Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, et al. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol. 2006;80:2418-2428.

    Not in our library10.1128/jvi.80.5.2418-2428.2006

  61. 61.

    Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, et al. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol. 2010;84:12048-12057.

    Not in our library10.1128/jvi.01063-10

  62. 62.

    Owen DM, Huang H, Ye J, Gale M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology. 2009;394:99-108.

    Not in our library10.1016/j.virol.2009.08.037

  63. 63.

    Cun W JJ, Luo G. The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus. J Virol. 2010;84:11532-11541.

    Not in our library10.1128/jvi.01021-10

  64. 64.

    Fazio S, Linton MF, Hasty AH, Swift LL. Recycling of apolipoprotein E in mouse liver. J Biol Chem. 1999;274:8247-8253.

    Not in our library10.1074/jbc.274.12.8247

  65. 65.

    Fazio S, Linton MF, Swift LL. The cell biology and physiologic relevance of ApoE recycling. Trends Cardiovasc Med. 2000;10:23-30.

    Not in our library10.1016/s1050-1738(00)00033-5

  66. 66.

    Hamilton RL, Wong JS, Guo LS, Krisans S, Havel RJ. Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res. 1990;31:1589-1603.

    Not in our library

  67. 67.

    Gusarova V SJ, Sullivan ML, Watkins SC, Brodsky JL, Fisher EA. Golgi-associated maturation of very low density lipoproteins involves conformational changes in apolipoprotein B, but is not dependent on apolipoprotein E. J Biochem. 2007;282:19453-19462.

    Not in our library10.1074/jbc.m700475200

  68. 68.

    Ullrich O RS, Urbé S, Zerial M, Parton RG. Rab11 regulates recycling through the pericentriolar recycling endosome. J Cell Biol. 1996;135:913-924.

    Not in our library10.1083/jcb.135.4.913

  69. 69.

    Casanova JE, Wang X, Kumar R, Bhartur SG, Navarre J, et al. Association of Rab25 and Rab11a with the apical recycling system of polarized Madin-Darby canine kidney cells. Mol Biol Cell. 1999;10:47-61.

    Not in our library10.1091/mbc.10.1.47

  70. 70.

    Chen W FY, Chen D, Wandinger-Ness A. Rab11 is required for trans-golgi network-to-plasma membrane transport and a preferential target for GDP dissociation inhibitor. Mol Biol Cell. 1998;9:3241-3257.

    Not in our library10.1091/mbc.9.11.3241

  71. 71.

    Bruce EA, Digard P, Stuart AD. The Rab11 pathway is required for influenza A virus budding and filament formation. J Virol. 2010;84:5848-5859.

    Not in our library10.1128/jvi.00307-10

  72. 72.

    Rowe RK, Suszko JW, Pekosz A. Roles for the recycling endosome, Rab8, and Rab11 in hantavirus release from epithelial cells. Virology. 2008;382:239-249.

    Not in our library10.1016/j.virol.2008.09.021

  73. 73.

    Chambers R, Takimoto T. Trafficking of Sendai virus nucleocapsids is mediated by intracellular vesicles. PLoS One. 2010;5:e10994.

    Not in our library10.1371/journal.pone.0010994

  74. 74.

    Söllner T BM, Whiteheart SW, Scheller RH, Rothman JE. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell. 1993;75:409-418.

    Not in our library10.1016/0092-8674(93)90376-2

  75. 75.

    Murray CL, Jones CT, Rice CM. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat Rev Microbiol. 2008;6:699-708.

    Not in our library10.1038/nrmicro1928

  76. 76.

    Ma Y, Anantpadma M, Timpe JM, Shanmugam S, Singh SM, et al. Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J Virol. 2011;85:86-97.

    Not in our library10.1128/jvi.01070-10

  77. 77.

    Bamberger MJLM. Possible role of the Golgi apparatus in the assembly of very low density lipoprotein. Proc Natl Acad Sci U S A. 1990;87:2390-2394.

    Not in our library10.1073/pnas.87.7.2390

  78. 78.

    Tran K T-TG, DeLong CJ, Cui Z, Shan J, Burton L, Jamieson JC, Yao Z. Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells. J Biol Chem. 2002;277:31187-31200.

    Not in our library10.1074/jbc.m200249200

  79. 79.

    Bonifacino JS L-SJ. Coat proteins: shaping membrane transport. Nat Rev Mol Cell Biol. 2003;4:409-414.

    Not in our library10.1038/nrm1099

  80. 80.

    Amako Y SG, Siddiqui A. Protein kinase D negatively regulates hepatitis C virus maturation through phosphorylation of oxysterol binding protein and ceramide transfer protein. 2011.

    Not in our library10.1074/jbc.m110.182097

  81. 81.

    Borawski J TP, Puyang X, Gibaja V, Zhao S, Mickanin C, et al. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol. 2009;83:10058-10074.

    Not in our library10.1128/jvi.02418-08

  82. 82.

    Trotard M, Lepere-Douard C, Regeard M, Piquet-Pellorce C, Lavillette D, et al. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. Faseb J. 2009;23:3780-3789.

    Not in our library10.1096/fj.09-131920

  83. 83.

    Folsch H. The building blocks for basolateral vesicles in polarized epithelial cells. Trends Cell Biol. 2005;15:222-228.

    Not in our library10.1016/j.tcb.2005.02.006

  84. 84.

    Li Q BA, Ng A, Hu Z, Xavier RJ, Liang TJ, Elledge SJ. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A. 2009;106:16410-16415.

    Not in our library10.1073/pnas.0907439106

  85. 85.

    Lai CK, Jeng KS, Machida K, Lai MM. Hepatitis C virus egress and release depend on endosomal trafficking of core protein. J Virol. 2010;84:11590-11598.

    Not in our library10.1128/jvi.00587-10

  86. 86.

    Egea G, Lazaro-Dieguez F, Vilella M. Actin dynamics at the Golgi complex in mammalian cells. Curr Opin Cell Biol. 2006;18:168-178.

    Not in our library10.1016/j.ceb.2006.02.007

  87. 87.

    Smith GA, Enquist LW. Break ins and break outs: viral interactions with the cytoskeleton of Mammalian cells. Annu Rev Cell Dev Biol. 2002;18:135-161.

    Not in our library10.1146/annurev.cellbio.18.012502.105920

  88. 88.
  89. 89.

    Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology. 2008;47:17-24.

    Not in our library10.1002/hep.21959

  90. 90.

    Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol. 2009;90:48-58.

    Not in our library10.1099/vir.0.006700-0

  91. 91.

    Mateu G, Donis RO, Wakita T, Bukh J, Grakoui A. Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. Virology. 2008;376:397-407.

    Not in our library10.1016/j.virol.2008.03.027

  92. 92.

    Martin BR GB, Adams SR, Tsien RY. Mammalian cell–based optimization of the biarsenical-binding tetracysteine motif for improved fluorescence and affinity. Nat Biotechnol. 2005;23:1308-1314.

    Not in our library10.1038/nbt1136

  93. 93.

    Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology. 2006;131:1584-1591.

    Not in our library10.1053/j.gastro.2006.08.043

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.